VitaLunga

About

Funding history · 1 round · — total

Q&A

What is VitaLunga's primary focus?

VitaLunga is a biotechnology startup developing a novel oral drug to treat and prevent aging-related diseases such as Alzheimer's and Parkinson's.

When was VitaLunga founded?

VitaLunga was founded in 2018.

Where is VitaLunga headquartered?

VitaLunga is headquartered in Jerusalem, Israel.

What is the scientific basis for VitaLunga's drug development?

VitaLunga's drug development is based on research from The Hebrew University's Faculty of Medicine. Their drug-design platform discovered novel compounds that facilitate potent autophagy and mitophagy in human cells.

What is VitaLunga's current stage of development?

VitaLunga is currently raising funds to begin preclinical studies for its novel oral drug.

Who are the founders of VitaLunga?

The founders of VitaLunga are Professor Einav Gross and Professor Shmuel Ben-Sasson, both researchers.

Has VitaLunga raised any funding?

VitaLunga completed a Seed funding round in November 2018.

What is VitaLunga's relationship with The Hebrew University of Jerusalem?

VitaLunga is a spinout from The Hebrew University of Jerusalem, with its technology originating from research at the university's Faculty of Medicine. Yissum, the university's technology transfer company, is also an affiliate.

Team · 2

Einav Gross

Founder · Professor and Researcher

Shmuel Ben-Sasson

Founder · Professor and Researcher

Sectors & technology